Nothing Special   »   [go: up one dir, main page]

ECSP045474A - 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 - Google Patents

1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6

Info

Publication number
ECSP045474A
ECSP045474A EC2004005474A ECSP045474A ECSP045474A EC SP045474 A ECSP045474 A EC SP045474A EC 2004005474 A EC2004005474 A EC 2004005474A EC SP045474 A ECSP045474 A EC SP045474A EC SP045474 A ECSP045474 A EC SP045474A
Authority
EC
Ecuador
Prior art keywords
sulphonylazaindols
hydroxythyriptamine
aminoalquil
ligands
disorders
Prior art date
Application number
EC2004005474A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045474A publication Critical patent/ECSP045474A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I) y el uso del mismo para el tratamiento terapéutico de desórdenes en relación o que afectan al receptor 5-HT6.
EC2004005474A 2002-06-04 2004-12-02 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 ECSP045474A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38550202P 2002-06-04 2002-06-04

Publications (1)

Publication Number Publication Date
ECSP045474A true ECSP045474A (es) 2005-01-28

Family

ID=29712180

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005474A ECSP045474A (es) 2002-06-04 2004-12-02 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6

Country Status (26)

Country Link
US (3) US6825212B2 (es)
EP (1) EP1509522B1 (es)
JP (1) JP2005532349A (es)
KR (1) KR20050013565A (es)
CN (1) CN1315827C (es)
AR (1) AR040047A1 (es)
AT (1) ATE355289T1 (es)
AU (1) AU2003239954A1 (es)
BR (1) BR0311591A (es)
CA (1) CA2486191A1 (es)
DE (1) DE60312155T2 (es)
DK (1) DK1509522T3 (es)
EC (1) ECSP045474A (es)
ES (1) ES2282637T3 (es)
HK (1) HK1071371A1 (es)
IL (1) IL165487A0 (es)
MX (1) MXPA04011331A (es)
NO (1) NO20044763L (es)
NZ (1) NZ536959A (es)
PT (1) PT1509522E (es)
RU (1) RU2315048C2 (es)
SI (1) SI1509522T1 (es)
TW (1) TW200408638A (es)
UA (1) UA78999C2 (es)
WO (1) WO2003101990A1 (es)
ZA (1) ZA200500022B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7528165B2 (en) 2001-12-13 2009-05-05 National Health Research Institutes Indole compounds
US7632955B2 (en) 2001-12-13 2009-12-15 National Health Research Institutes Indole compounds
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
MXPA05008441A (es) * 2003-02-14 2005-10-19 Wyeth Corp Derivados de heterociclil-3-sulfonilindazol o azaindazol como ligandos de 5-hidroxitriptamina-6.
EP1694671A2 (en) 2003-12-04 2006-08-30 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
AU2005228904C1 (en) 2004-03-30 2012-12-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
BRPI0511874A (pt) 2004-06-09 2008-01-15 Glaxo Group Ltd derivados da pirrolopiridina
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
WO2006017443A2 (en) * 2004-08-02 2006-02-16 Osi Pharmaceuticals, Inc. Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds
EP1824464A1 (en) * 2004-12-14 2007-08-29 Wyeth a Corporation of the State of Delaware Use of a 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2006138549A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
TWI473808B (zh) 2005-06-22 2015-02-21 Plexxikon Inc 用於激酶調節的化合物及方法及其適應症
WO2007027855A2 (en) * 2005-09-01 2007-03-08 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
NZ569899A (en) 2006-01-17 2011-06-30 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
CN101678014B (zh) * 2007-05-21 2012-12-12 Sgx药品公司 杂环激酶调节剂
CA2695004C (en) 2007-07-17 2016-01-19 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009082268A2 (ru) 2007-12-21 2009-07-02 Alla Chem, Llc ЛИГАНДЫ α-АДРЕНОЦЕПТОРОВ, ДОПАМИНОВЫХ, ГИСТАМИНОВЫХ, ИМИДАЗОЛИНОВЫХ И СЕРОТОНИНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
EP2955180B1 (en) 2009-04-03 2018-01-10 F. Hoffmann-La Roche AG Propane-i-sulfonic acid {3- [5- (4- chloro-phenyl) -1h-pyrrolo [2, 3-b} pyridine-3-carbonyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
AP3631A (en) 2009-06-17 2016-03-08 Vertex Pharma Inhibitors of influenza viruses replication
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
EP2566481A4 (en) * 2010-05-06 2014-01-22 Merck Sharp & Dohme AS FAAH MODULATORS SUITABLE AZA-INDOL DERIVATIVES
EP2651940A1 (en) 2010-12-16 2013-10-23 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2012109075A1 (en) 2011-02-07 2012-08-16 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AR085279A1 (es) 2011-02-21 2013-09-18 Plexxikon Inc Formas solidas de {3-[5-(4-cloro-fenil)-1h-pirrolo[2,3-b]piridina-3-carbonil]-2,4-difluor-fenil}-amida del acido propano-1-sulfonico
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
PT3068782T (pt) 2013-11-13 2018-10-08 Vertex Pharma Métodos de preparação de inibidores da replicação de vírus da gripe
ES2741444T3 (es) 2013-11-13 2020-02-11 Vertex Pharma Inhibidores de la replicación de virus de la gripe
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
AU2020229779A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California Azepino-indoles and other heterocycles for treating brain disorders
WO2021252692A1 (en) * 2020-06-10 2021-12-16 Delix Therapeutics, Inc. Isotryptamine psychoplastogens and uses thereof
KR102347368B1 (ko) * 2020-11-03 2022-01-07 (주)케이메디켐 신규한 아자인돌 유도체, 이의 제조방법 및 이를 포함하는 인지기능 개선용 조성물

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US625923A (en) * 1899-05-30 Magneto-bell striker
US4654360A (en) 1984-06-01 1987-03-31 Syntex (U.S.A.) Inc. 1,2,3-trisubstituted indoles for treatment of inflammation
FR2642755B1 (es) * 1989-02-07 1993-11-05 Sanofi
US5132319A (en) * 1991-03-28 1992-07-21 Merck Frosst Canada, Inc. 1-(hydroxylaminoalkyl) indole derivatives as inhibitors of leukotriene biosynthesis
GB9503377D0 (en) 1995-02-21 1995-04-12 Merck Sharp & Dohme Therapeutic agents
US6194410B1 (en) * 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
PL198983B1 (pl) * 1998-04-28 2008-08-29 Elbion Ag Nowe hydroksyindole, ich zastosowanie jako inhibitorów fosfodiesterazy 4 oraz sposoby ich wytwarzania
AU779832B2 (en) 1999-08-12 2005-02-10 Nps Pharmaceuticals, Inc. Azaindoles having serotonin receptor affinity
SK15432002A3 (sk) 2000-04-28 2004-01-08 Baxter Healthcare Sa 2-acylindolové deriváty a ich použitie ako protinádorového prípravku
SK16052003A3 (en) * 2001-06-07 2004-10-05 Hoffmann La Roche New indole derivatives with 5-HT6 receptor affinity
EP1414442A1 (en) 2001-08-07 2004-05-06 Smithkline Beecham Plc 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders
DE60309852T2 (de) 2002-03-27 2007-06-06 Glaxo Group Ltd., Greenford Chinolin- und aza-indolderivate und deren verwendung als 5-ht6 liganden
UA78999C2 (en) * 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6

Also Published As

Publication number Publication date
ES2282637T3 (es) 2007-10-16
US7585873B2 (en) 2009-09-08
SI1509522T1 (sl) 2007-06-30
AU2003239954A1 (en) 2003-12-19
US20030236278A1 (en) 2003-12-25
JP2005532349A (ja) 2005-10-27
DK1509522T3 (da) 2007-04-16
US20060148831A1 (en) 2006-07-06
US6825212B2 (en) 2004-11-30
DE60312155T2 (de) 2007-11-22
UA78999C2 (en) 2007-05-10
US20050085481A1 (en) 2005-04-21
ZA200500022B (en) 2006-06-28
TW200408638A (en) 2004-06-01
EP1509522A1 (en) 2005-03-02
CN1315827C (zh) 2007-05-16
NZ536959A (en) 2007-04-27
BR0311591A (pt) 2005-03-01
KR20050013565A (ko) 2005-02-04
AR040047A1 (es) 2005-03-09
NO20044763L (no) 2005-02-28
CN1659166A (zh) 2005-08-24
IL165487A0 (en) 2006-01-15
ATE355289T1 (de) 2006-03-15
WO2003101990A1 (en) 2003-12-11
MXPA04011331A (es) 2005-02-14
US7074792B2 (en) 2006-07-11
HK1071371A1 (en) 2005-07-15
EP1509522B1 (en) 2007-02-28
RU2004139068A (ru) 2005-06-27
CA2486191A1 (en) 2003-12-11
DE60312155D1 (de) 2007-04-12
RU2315048C2 (ru) 2008-01-20
PT1509522E (pt) 2007-05-31

Similar Documents

Publication Publication Date Title
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
ECSP088283A (es) Compuestos de piridina 5- (fenilisoxazoliletoxi) -triazol- 3-ilo substituidos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ECSP055536A (es) Derivados de 1-heterociclilalquil-3-sulfonilindol o indazol como ligandos de 5-hidroxitriptamina-6
ECSP055535A (es) Derivados de 1-heterociclialquil-3-sulfonilazaindol o azaindol como ligandos de 5-hidroxitriptamina-6
UY28150A1 (es) Agentes terapeuticos
UY29246A1 (es) Nuevos compuestos
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
ECSP099413A (es) COMPUESTOS A BASE DE 4 - fenil - 6 - (2,2,2 - trifluoro - 1 - feniletoxi)pirimidina Y MÉTODOS PARA SU EMPLEO
UY29253A1 (es) 3-amino-pirazol(3,4b)piridinas como inhibidores de proteintirosinquinasas, su preparación y uso como medicamento
UY27714A1 (es) 2 - heteroaril - pirimidinas inhibidoras de cdk, su preparación y su uso como medicamentos.
UY27939A1 (es) Compuestos
UY28144A1 (es) Agentes terapéuticos
PA8680701A1 (es) Derivados de oxindol
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
ECSP066365A (es) Anilino purinas sustituidas en la posición 6 útiles como inhibidores de rtk
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
UY28945A1 (es) Derivados de pirrolopiridina
UY28839A1 (es) Agentes terapeuticos